Evolving Issues in Diabetic Macular Edema: New Medications and Drug Delivery Technologies- Diabetic macular edema (DME) is the major cause of vision loss in people with diabetic retinopathy. In recent years, results from several clinical trials have been published including the Diabetic Retinopathy Clinical Research Network’s “Protocol H” trial, the READ-2 trial, the RESOLVE trial, “Protocol I” trial, RESTORE, and FAME. Furthermore, new delivery system technology has been developed and is being introduced into the armamentarium of clinical practice. Results from several studies assessing the safety and efficacy of steroids using different delivery methods for the management of DME have been recently announced and even more will be announced in the near future. In addition to steroids, results from trials using laser therapy, vascular endothelial growth factor (VEGF) inhibitors and other approaches are breaking into clinical practice. With all these emerging opportunities for DME, it is incumbent on the ophthalmologist to remain well informed and aggressive with rapid diagnosis and optimal treatment.
Analyze the safety and efficacy of ophthalmic preparations used to manage DME.
Evaluate the results of the latest clinical trials for the management of DME to determine best practices.
1.5 Free AMA Pra CAT 1 CME for Physicians
Expires 6/15/14
Presented by Johns Hopkins University School of Medicine
Grant by: Alimera Sciences, Inc
